Evidence map›Paper›PMID 18625776›Full record

Trial reportAntimicrobial agents and chemotherapy2008

Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae.

Alexey Ruzin, Frederick W Immermann, Patricia A Bradford

Open access · greenAbstract readClinical Trial, Phase III
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022
    Review
  6. Article
  7. Article
  8. Characterization of Tigecycline-HeteroresistantFrontiers in microbiology · 2021
    Article
  9. In Vivo Development of Polymyxin B Resistance inBioMed research international · 2020
    Article
  10. Mode of Action of the Monobactam LYS228 and Mechanisms DecreasingAntimicrobial agents and chemotherapy · 2018
    Article
  11. Article
  12. Article
  13. The Rapid Emergence of Tigecycline Resistance inFrontiers in microbiology · 2018
    Article
  14. Article
  15. Article
  16. Tetracycline Antibiotics and Resistance.Cold Spring Harbor perspectives in medicine · 2016
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Alexey RuzinDepartment of Infectious Disease, Wyeth Research, Pearl River, New York 10965, USA. ruzina@wyeth.com
Frederick W Immermann
Patricia A Bradford
Pearl River Community College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical isolates of Klebsiella pneumoniae were tested for a correlation between tigecycline MIC and expression of ramA by using real-time PCR. At MICs of 4 and 8 microg/ml, the expression of ramA was statistically significantly different from MICs of 2 microg/ml or less, supporting the tigecycline susceptibility breakpoint of <or=2 microg/ml for K. pneumoniae.

Indexed as

Anti-Bacterial AgentsBacterial ProteinsDrug Resistance, Multiple, BacterialHumansKlebsiella InfectionsKlebsiella pneumoniaeMembrane Transport ProteinsMicrobial Sensitivity TestsMinocyclinePolymerase Chain ReactionTigecyclineAnti-Bacterial AgentsBacterial ProteinsMembrane Transport ProteinsMinocyclineRamA protein, KlebsiellaTigecycline

Identifiers

PMID18625776
PMCPMC2533484
OpenAlexW2126661550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.